Cytek Biosciences Statistics
Want to see CTKB full AI Analyst Report?
Cytek Biosciences (CTKB) Stock Statistics & Valuation Metrics
Total Valuation
Cytek Biosciences has a market cap or net worth of $757.24M. The enterprise value is $553.65M.
- Market Cap
- $757.24M
- Enterprise Value
- $553.65M
Share Statistics
Cytek Biosciences has 130,783,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 130,783,970
- Owned by Insiders
- 8.42%
- Owned by Institutions
- 25.98%
Financial Efficiency
Cytek Biosciences’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -10.28%.
- Return on Equity (ROE)
- -0.19
- Return on Assets (ROA)
- -0.14
- Return on Invested Capital (ROIC)
- -10.28%
- Return on Capital Employed (ROCE)
- -0.11
- Revenue Per Employee
- 287.85K
- Profits Per Employee
- -95.06K
- Employee Count
- 700
- Asset Turnover
- 0.44
- Inventory Turnover
- 2.00
Valuation Ratios
The current PE Ratio of Cytek Biosciences is -9.14. Cytek Biosciences’s PEG ratio is 0.03.
- PE Ratio
- -9.14
- PS Ratio
- 3.63
- PB Ratio
- 2.34
- Price to FCF
- -55.87
- Price to Operating Cash Flow
- -113.92
- PEG Ratio
- 0.03
Income Statement
In the last 12 months, Cytek Biosciences had revenue of 201.49M and earned -66.54M in profits. Earnings per share was -0.52.
- Revenue
- 201.49M
- Gross Profit
- 104.46M
- Operating Income
- -40.38M
- Pretax Income
- -29.84M
- Net Income
- -66.54M
- EBITDA
- -17.39M
- Earnings Per Share (EPS)
- -0.52
Cash Flow
In the last 12 months, operating cash flow was -6.59M and capital expenditures -6.89M, giving a free cash flow of -13.48M billion.
- Operating Cash Flow
- -6.59M
- Free Cash Flow
- -13.48M
- Free Cash Flow per Share
- -0.10
Dividends & Yields
Cytek Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.79%
- Earnings Yield
- -10.82%
Stock Price Statistics
- Beta
- 0.80
- 52-Week Price Change
- 20.25%
- 50-Day Moving Average
- 5.39
- 200-Day Moving Average
- 4.65
- Relative Strength Index (RSI)
- 51.89
- Average Volume (3m)
- 1.26M
Important Dates
Cytek Biosciences upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Cytek Biosciences as a current ratio of 5.04, with Debt / Equity ratio of 6.95%
- Current Ratio
- 5.04
- Quick Ratio
- 4.42
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 3.86
- Interest Coverage Ratio
- -85.20
Taxes
In the past 12 months, Cytek Biosciences has paid 36.70M in taxes.
- Income Tax
- 36.70M
- Effective Tax Rate
- -1.23
Enterprise Valuation
Cytek Biosciences EV to EBITDA ratio is -24.02, with an EV/FCF ratio of -52.70.
- EV to Sales
- 3.42
- EV to EBITDA
- -24.02
- EV to Free Cash Flow
- -52.70
- EV to Operating Cash Flow
- -107.80
Balance Sheet
Cytek Biosciences has $255.90M in cash and marketable securities with $24.69M in debt, giving a net cash position of $231.21M billion.
- Cash & Marketable Securities
- $255.90M
- Total Debt
- $24.69M
- Net Cash
- $231.21M
- Net Cash Per Share
- $1.77
- Tangible Book Value Per Share
- $2.23
Margins
Gross margin is 54.75%, with operating margin of -21.13%, and net profit margin of -39.10%.
- Gross Margin
- 54.75%
- Operating Margin
- -21.13%
- Pretax Margin
- -19.24%
- Net Profit Margin
- -39.10%
- EBITDA Margin
- -14.25%
- EBIT Margin
- -18.51%
Analyst Forecast
The average price target for Cytek Biosciences is $6.13, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $6.13
- Price Target Upside
- 6.34% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 5.50%
- EPS Growth Forecast
- -524.33%
Scores
- Smart Score
- 6
- AI Score
- 54
